Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360371 · ClinicalTrials.gov registry record · Phase 2
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02360371: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02360371 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02360371, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Within-subject, double-blind, placebo-controlled examination of opioid abuse potential in healthy individuals as a function of A118G SNP on the OPRM1 gene.
Interventions
- DRUG Within-subject test of blinded study medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-04 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02360371
The ClinicalTrials.gov registry entry for NCT02360371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Within-subject test of blinded study medication is the first listed.
NCT02360371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02360371 about?
NCT02360371 is a clinical study titled "A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans". Within-subject, double-blind, placebo-controlled examination of opioid abuse potential in healthy individuals as a function of A118G SNP on the OPRM1 gene.
What is the current status of trial NCT02360371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2015-04. Estimated completion is 2021-05.
What interventions are being tested in trial NCT02360371?
The interventions under investigation include: Within-subject test of blinded study medication (DRUG).
Who is sponsoring clinical trial NCT02360371?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.